Drugs that contain Bupropion Hydrochloride; Naltrexone Hydrochloride
1. Contrave patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278544 | NALPROPION | Compositions for affecting weight loss |
Apr, 2024
(3 days ago) | |
| US8815889 | NALPROPION | Compositions and methods for increasing insulin sensitivity |
Jul, 2024
(2 months from now) | |
| US7462626 | NALPROPION | Compositions for affecting weight loss |
Jul, 2024
(2 months from now) | |
| US7375111 | NALPROPION | Compositions for affecting weight loss |
Mar, 2025
(10 months from now) | |
| US9107837 | NALPROPION | Sustained release formulation of naltrexone |
Jun, 2027
(3 years from now) | |
| US8722085 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(3 years from now) | |
| US8318788 | NALPROPION | Layered pharmaceutical formulations |
Nov, 2027
(3 years from now) | |
| US10307376 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(3 years from now) | |
| US9125868 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(3 years from now) | |
| US8088786 | NALPROPION | Layered pharmaceutical formulations |
Feb, 2029
(4 years from now) | |
| US11324741 | NALPROPION | Methods for treating visceral fat conditions |
May, 2029
(5 years from now) | |
| US8916195 | NALPROPION | Sustained release formulation of naltrexone |
Feb, 2030
(5 years from now) | |
| US11033543 | NALPROPION | Methods of providing weight loss therapy in patients with major depression |
Jan, 2031
(6 years from now) | |
| US9248123 | NALPROPION | Methods of providing weight loss therapy in patients with major depression |
Jan, 2032
(7 years from now) | |
| US11139056 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(9 years from now) | |
| US10403170 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(9 years from now) | |
| US9633575 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(9 years from now) | |
| US10231964 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(10 years from now) | |
| US10835527 | NALPROPION | Compositions and methods for reducing major adverse cardiovascular events |
Jul, 2034
(10 years from now) | |
| US10828294 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance; Use of naltrexone and bupropion in extended-release form f...
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage
CONTRAVE family patents
